Hypertrophic cardiomyopathy (HCM), is one of the most common genetic diseases, which may affect as many as 1 in 500 individuals. It causes abnormal thickening of the heart muscle, and patients may either be completely asymptomatic or suffer from life-threatening arrhythmias, heart failure, or even sudden cardiac death. UT Southwestern has one of only 39 centers in the United States recognized by the Hypertrophic Cardiomyopathy Association as being a specialized “Center of Excellence” in the management of HCM and two of our faculty – Drs. Mark Link and Jose Joglar – were on the committee that wrote the guidelines, published In November, for modern treatment of this challenging disease.
Part of the conventional wisdom about HCM is that it is particularly dangerous for those who have it to participate in high-intensity athletics because early reports identified HCM in nearly half of athletes who died suddenly during sports. However, recent data have challenged this paradigm. For example, some patients with HCM, almost all with an implanted defibrillator, chose to continue to play sports despite their doctor's proscription, and did quite well. More recently, in a large, multicenter study, HCM patients were able to participate in a moderate-intensity exercise program safely, though the gains in fitness were modest.